

Curriculum Vitae

Personal information

Stefania Bellino

Work experience

1. Employer: Istituto Superiore di Sanità
 - Start date: 2005
 - End date: present
 - Position: Research Director
 - Activities: Epidemiology of infectious diseases, public health surveillance; Phase 1/3 clinical trials authorization in Italy; marketing authorization and scientific advice of new drugs in centralized European procedures of EMA.
 - Country: Italy
2. Employer: Informa, Contract Research Organization
 - Start date: 1998
 - End date: 2008
 - Position: Head of the Biostatistics and Data Management Unit
 - Activities: drafting of clinical protocols, particularly for the study design, determination of sample size and statistical analysis plan; statistical analysis of clinical trials (Phases I-IV) and observational studies; preparation of statistical/clinical reports at the conclusion of the studies, according to ICH guidelines; data management activities for data quality control and database structuring.
 - Country: Italy

Education and training

1. Subject: Mediterranean School of Epidemiology and Statistical Methods in Biomedical Research
 - Start date: 06/2003
 - End date: 06/2003
 - Qualification: Categorical data analysis e Analysis of longitudinal studies
 - Organisation: National Research Council
 - Country: Italy
2. Subject: Postgraduate specialization
 - Start date: 1999
 - End date: 2002
 - Qualification: Specialization in Health Statistics
 - Organisation: University of Rome "La Sapienza"
 - Country: Italy
3. Subject: British Council
 - Start date: 1997
 - End date: 1997
 - Qualification: First Certificate in English
 - Organisation: University of Cambridge
 - Country: Italy
4. Subject: Course for programmer
 - Start date: 1997
 - End date: 1997
 - Qualification: programming in Cobol-Cics-DB2
 - Organisation: Selfin-IBM
 - Country: Italy
5. Subject: University Degree
 - Start date: 1989
 - End date: 1995
 - Qualification: Degree in Statistical Sciences
 - Organisation: University of Rome "La Sapienza"
 - Country: Italy

Additional information

Publications

H-Index (Scopus): 25
Total number of citations (Scopus): 1732
Total number of publications: 70
Abstracts for scientific conferences: 39
Scientific Reports: 19
Assessor for Centralised procedures for marketing authorisation for EMA: 16

Publications

1. Fanciulli G, **Bellino S**, La Salvia A. Quality of outcome reporting for clinical trials on medullary thyroid cancer registered on ClinicalTrials.gov. *Minerva Endocrinology* 2023. doi: 10.23736/S2724-6507.23.04034-4. (IF 3.76)
2. Balboni E, Filippini T, Rothman KJ, Costanzini S, **Bellino S**, Pezzotti P, Brusaferrero S, Ferrari F, Orsini N, Teggi S, Vinceti M. The influence of meteorological factors on COVID-19 spread in Italy during the first and second wave. *Environmental Research* 2023; ;228:115796 (IF 8.43)
3. **Bellino S**. COVID-19 treatments approved in the European Union and clinical recommendations for the management of non-hospitalized and hospitalized patients. *Annals of Medicine* 2022;54(1):2856–2860 (IF 5.35)
4. Díez-Domingo J, Torcel-Pagnon L, Carmona A, Launay O , Dos Santo G , Rizzo C , Haag M , Stuurman A, Nauta J, Vannacci A , de Lusignan S, del Rey E, Levi M, Lina B, **Bellino S**, Samantha Nye S, Neels P, Hanna Nohynek H, Mahé C, on behalf of the DRIVE consortium. The value of public-private collaborative Real-World Evidence platforms to monitor vaccine performance post authorization: DRIVE - a European initiative. *Expert Review of Vaccines* 2022;1-10.doi: 10.1080/14760584.2022.2137144 (IF 5.68)
5. Vinceti M, Balboni E, Rothman KJ, Teggi S, **Bellino S**, Pezzotti P, Ferrari F, Orsini N, Filippini T. Substantial impact of mobility restrictions on reducing COVID-19 incidence in Italy in 2020. *Journal of Travel Medicine* 2022;taac081 (IF 39.19)
6. Spada E, Taffon S, Simeoni M, Martina A, Pati I, Villano U, Adriani D, D'Angiò A, Tritarelli E, **Bellino S**, Boros S, Urciuoli R, Masiello F, Marano G, Bruni R, Pezzotti P, Ciccaglione AR, Pupella S, De Angelis V, Pisani G. Prevalence and risk factors for hepatitis E virus infection in blood donors: a nationwide survey in Italy, 2017 to 2019. *Eurosurveillance* 2022;27(22) (IF 21.29)
7. **Bellino S**. COVID-19 vaccines approved in the European Union: current evidence and perspectives. *Expert Review of Vaccines* 2021;20(10):1195-1199 (IF 5.68)
8. Fabiani M, Mateo-Urdiales A, Andrianou X, Bella A, Del Manso M, **Bellino S**, Rota MC, Boros S, Vescio MF, D'Ancona F, Siddu A, Punzo O, Filia A, Brusaferrero S, Rezza G, Dente MG, Declich S, Pezzotti P, Riccardo F for COVID-19 working group. Epidemiological characteristics of COVID-19 cases in non-Italian nationals diagnosed in Italy: results from the national integrated surveillance system. *European Journal of Public Health* 2021;31(1):37-44 (IF 4.42)
9. Borghetti A, **Bellino S**, Lombardi F, Whalen M, Moschese D, Ciccullo A, Tamburrini A, Baldin G, Dusina A, Visconti E, Emiliozzi A, Lamonica S, Belmonti S, Pezzotti P, Di Giambenedetto S. Risk of tumour onset in HIV+ patients on two-drug regimens: a cohort study in an Italian hospital. *AIDS Research and Human Retroviruses* 2021;37(5):350-356 (IF 1.72)
10. Sorgentone S, Busani L, Calistri P, Robuffo G, **Bellino S**, Acciari V, Ferri M, Graziani C, Antoci S, Lodi F, Alfonsi V, Cammà C, Fazii P, Andrianou X, Cito F, Lombardi G, Centorotola G, D'Amario M, D'Alterio N, Savini V, De Massis F, Pelatti A, Di Domenico M, Di Donato G, Di Giannatale E, Di Marcantonio L, Di Marzio V, Di Serafino G, Janowicz A, Marfoglia C, Marotta F, Morelli D,

Migliorati G, Neri D, Pomilio F, Scattolini S, Rezza G, Caponetti A, Pezzotti P, Garofolo G. A large foodborne outbreak of campylobacteriosis in kindergartens and primary schools of Pescara, Italy, May-June 2018. *Journal of Medical Microbiology* 2021;70(3) (IF 3.20)

11. Punzo O, **Bellino S**, Palmieri L, Lo Noce C, Giuliano M, Meli P, Boros S, Bella A, Patrizio P, Onder G and the COVID-19 mortality and surveillance groups. Clinical characteristics of individuals under 40 years of age who died with COVID-19 in Italy. *Journal of Medical Virology* 2021;93:1932-1936. (IF 20.69)
12. Amoroso A, Paola Magistroni P, Vespasiano F, Bella A, **Bellino S**, Puoti F, Alizzi S, Vaisitti T, Boros S, Grossi PA, Trapani S, Lombardini L, Pezzotti P, Brusaferro S, Cardillo M, on behalf of the Italian Network of Regional Transplant Coordinating Centers. HLA and AB0 polymorphisms influence SARS-CoV-2 infection and COVID-19 severity. *Transplantation* 2021; 105(1):193-200. (IF 5.28)
13. Iacchini S, **Bellino S**, D'Ancona F, Del Grosso M, Camilli R, Errico G, Pezzotti P, Pantosti P, Monaco M, Referenti Regionali della rete AR-ISS. National surveillance of antibiotic-resistance AR-ISS, first six months 2020 data. *Bollettino Epidemiologico Nazionale* 2020;1(2):46-50.
14. **Bellino S**, Rota MC, Riccardo F, Andrianou X, Mateo Urdiales A, Del Manso M, Punzo O, Bella A, Villani A, Patrizio P, and the COVID-19 Working Group. Pediatric COVID-19 cases prelockdown and postlockdown in Italy. *Pediatrics*. 2021;147(2):e2020035238. (IF 9.70)
15. **Bellino S**, Punzo O, Rota MC, Del Manso M, Mateo Urdiales A, Andrianou X, Fabiani M, Boros S, Vescio F, Riccardo F, Bella A, Filia A, Rezza G, Villani A, Patrizio P, and the COVID-19 Working Group. COVID-19 disease severity risk factors for pediatric patients in Italy. *Pediatrics* 2020;146(1):e2020009399 (IF 7.13)
16. Riccardo F, Ajelli M, Andrianou X, Bella A, Del Manso M, Fabiani M, **Bellino S**, Boros S, Mateo Urdiales A, Marziano V, Rota MC, Filia A, D'Ancona F, Siddu A, Punzo O, Trentini F, Guzzetta G, Poletti P, Stefanelli P, Castrucci MR, Ciervo A, Di Benedetto C, Tallon M, Piccioli A, Brusaferro S, Rezza G, Merler S, Pezzotti P for COVID-19 working group. Epidemiological characteristics of COVID-19 cases in Italy and estimates of the reproductive numbers one month into the epidemic. *Eurosurveillance* 2020;25(49):2000790. (IF 6.31)
17. Del Manso M, Andrianou X, Mateo-Urdiales A, Vescio MF, Rota MC, Fabiani M, Boros S, **Bellino S**, Stefanelli P, Ciervo A, Punzo O, Filia A, Tallon M, Di Benedetto C, Spuri M, Pezzotti P, Riccardo F, Bella A per il Gruppo Referenti regionali della Sorveglianza Integrata Covid-19. La Sorveglianza Integrata COVID-19 in Italia: output e attività correlate [COVID-19 Integrated Surveillance in Italy: outputs and related activities]. *Epidemiologia & Prevenzione* 2020;44(5-6 Suppl 2):70-80. (IF 1.90)
18. Guzzetta G, Riccardo F, Marziano V, Poletti P, Trentini F, Bella A, Andrianou X, Del Manso M, Fabiani M, **Bellino S**, Boros S, Mateo Urdiales A, Vescio MF, Brusaferro S, Rezza G, Pezzotti P, Ajelli M, Merler S. Impact of a Nationwide Lockdown on SARS-CoV-2 Transmissibility, Italy. *Emerging Infectious Diseases* 2020; 20;27(1). (IF 16.13)
19. **Bellino S**, Piovesan C, Rizzo C, Bella A, Pezzotti P, Ramigni M. Determinants of vaccination uptake, and influenza vaccine effectiveness in preventing deaths and hospital admissions in the elderly population; Treviso, Italy, 2014/2015-2016/2017 seasons. *Human Vaccines & Immunotherapeutics* 2020;16(2):301-312 (IF 3.45)
20. Stefanelli P, **Bellino S**, Fiore S, Fontana S, Amato C, Buttinelli G, and the

National Surveillance System of AFP Collaborative Centres. Acute flaccid paralysis cases 2007-2016 in Italy: hospital-discharges based searches and comparison with data of the National Surveillance System. BMC Public Health 2019; 19(1):1532 (IF 2.52)

21. **Bellino S**, Bella A, Puzelli S, Di Martino A, Facchini M, Punzo O, Pezzotti P, Castrucci MR, and the Influnet Study Group. Moderate influenza vaccine effectiveness against A(H1N1)pdm09 virus, and low effectiveness against A(H3N2) subtype, 2018/19 season in Italy. Expert Review of Vaccines 2019; 18(11):1201-1209. (IF 4.36)
22. Sgadari C, Monini P, Tripiciano A, Picconi O, Casabianca A, Chiara Orlandi C, Moretti S, Francavilla V, Arancio A, Paniccia G, Campagna M, **Bellino S**, Meschiari M, Nozza S, Sighinolfi L, Latini A, Muscatello A, Saracino A, Di Pietro M, Galli M, Cafaro A, Magnani M, Ensoli F, Ensoli B. Continued decay of HIV proviral DNA upon vaccination with HIV-1 Tat of subjects on long-term ART: an 8-year follow-up study. Frontiers in Immunology 2019; 10(233):1-19 (IF 5.51)
23. **Bellino S**, Borghetti A, Lombardi F, Camoni L, Ciccullo A, Baldin G, Belmonti S, Moschese D, Lamonica S, Cauda R, Pezzotti P, Di Giambenedetto S. Trends of hospitalizations rates in a cohort of HIV-infected persons followed in an Italian hospital from 1998 to 2016. Epidemiology and Infection 2017; 147:e89 (IF 2.15)
24. Pezzotti P, **Bellino S**, Riccardo F, Lucaroni F, Cerquetti M, Pantosti A, Rezza G, Stefanelli P. Vaccine preventable invasive bacterial diseases in Italy: a comparison between the national surveillance system and recorded hospitalizations, 2007-2016. Vaccine 2019; 37: 41-48. (IF 3.14)
25. Pezzotti P, **Bellino S**, Prestinaci F, Iacchini S, Stefanelli P, Rezza G. Reply to letters to the Editor. Vaccine 2018; 36:5508-5509. (IF 3.27)
26. Pezzotti P, **Bellino S**, Prestinaci F, Iacchini S, Lucaroni F, Camoni L, Barbieri M, Ricciardi W, Stefanelli P, Rezza G. The impact of immunization programs on 10 vaccine preventable diseases in Italy: 1900-2015. Vaccine 2018; 36:1435-1443. (IF=3.27)
27. Fedele G, Leone P, **Bellino S**, Schiavoni I, Pavia C, Lazzarotto T, Stefanelli P. Diagnostic performance of commercial serological assays measuring *Bordetella pertussis* IgG antibodies. Diagnostic Microbiology and Infectious Diseases 2018. 90(3):157-162. (IF 2.40)
28. Torre M, Romanini E, Zanolli G, Carrani E, Luzi I, Leone L, **Bellino S**. Monitoring outcome of joint arthroplasty in Italy: the implementation of the national registry. Joints 2017; 5:70-78. (IF 1.13)
29. Ensoli B, Nchabeleng M, Ensoli F, Tripiciano A, **Bellino S**, Picconi O, Sgadari C, Longo O, Tavoschi L, Joffe D, Cafaro A, Francavilla V, Moretti S, Pavone Cossut MR, Arancio A, Paniccia G, Casabianca A, Magnani M, Buttò S, Levendal E, Velaphi Ndimande J, Asia B, Pillay Y, Garaci E, Monini P. HIV-Tat immunization induces cross-neutralizing antibodies and CD4+ T-cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial. Retrovirology 2016; 13(1):34. (IF 3.87)
30. Ensoli F, Cafaro A, Casabianca A, Tripiciano A, **Bellino S**, Longo O, Francavilla V, Picconi O, Sgadari C, Moretti S, Pavone Cossut MR, Arancio A, Orlandi C, Sernicola L, Maggiorella MT, Paniccia G, Mussini C, Lazzarin A, Sighinolfi L, Palamara G, Gori A, Angarano G, Di Pietro M, Galli M, Mercurio VS, Castelli F, Di Perri G, Monini P, Magnani M, Garaci E, Ensoli B. HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: results of a randomized phase II clinical trial. Retrovirology 2015; 12(1):33. (IF 3.99)

31. Cafaro A, Tripiciano A, Sgadari C, **Bellino S**, Picconi O, Longo O, Francavilla V, Buttò S, Titti F, Monini P, Ensoli F, Ensoli B. Development of a novel AIDS vaccine: the HIV-1 Tat protein vaccine. *Expert Opinion on Biological Therapy* 2015; 15(Suppl 1):13-29. (IF 3.44)
32. **Bellino S**, Tripiciano A, Picconi O, Francavilla V, Longo O, Sgadari C, Paniccia G, Arancio A, Angarano A, Ladisa N, Lazzarin A, Tambussi G, Nozza S, Torti C, Focà E, Palamara G, Latini A, Sighinolfi L, Mazzotta M, Di Pietro M, Di Perri G, Bonora S, Mercurio VS, Mussini C, Gori A, Galli M, Monini P, Cafaro A, Ensoli F, Ensoli B. The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4⁺ T-cell decay and viral load, and with delay of disease progression: results of a 3-year cohort study. *Retrovirology* 2014; 11:49. (IF 4.18)
33. Borsetti A, Ferrantelli F, Maggiorella MT, Sernicola L, **Bellino S**, Gallinaro A, Farcomeni S, Mee ET, Rose NJ, Cafaro A, Titti F, Ensoli B. Effect of MHC haplotype on immune response upon experimental SHIVSF162P4cy infection of Mauritian cynomolgus macaques. *PLoS One* 2014; 9(4):e93235. (IF 3.23)
34. Titti F, Maggiorella MT, Ferrantelli F, Sernicola L, **Bellino S**, Collacchi B, Fanales Belasio E, Moretti S, Pavone Cossut MR, Belli R, Olivieri E, Farcomeni S, Compagnoni D, Michelini Z, Sabbatucci M; Sparnacci K, Tondelli L, Laus M, Cafaro A, Caputo A, Ensoli B. Biocompatible anionic polymeric microspheres as priming delivery system for effective HIV/AIDS Tat-based vaccines. *PLoS ONE* 2014; 9(10):e111360. (IF 3.23)
35. Barillari G, Iovane A, Bacigalupo I, Palladino C, **Bellino S**, Leone P, Monini P, Ensoli B. Ritonavir or saquinavir impair the invasion of cervical intraepithelial neoplasia cells via a reduction of MMP expression and activity. *AIDS* 2012; 26(8):909-919. (IF 6.41)
36. Monini P, Cafaro A, Srivastava IK, Moretti S, Sharma VA, Andreini C, Chiozzini C, Ferrantelli F, Pavone Cossut MR, Tripiciano A, Nappi F, Longo O, **Bellino S**, Picconi O, Fanales-Belasio E, Borsetti A, Toschi E, Schiavoni I, Bacigalupo I, Kan E, Sernicola L, Maggiorella MT, Montin K, Porcu M, Leone Patrizia, Leone Pasqualina, Collacchi B, Palladino C, Ridolfi B, Falchi M, Macchia I, Ulmer JB, Buttò S, Sgadari C, Magnani M, Federico MPM, Titti F, Banci L, Dallochio F, Rappuoli R, Ensoli F, Barnett SW, Garaci E, Ensoli B. HIV-1 Tat promotes integrin-mediated HIV transmission to dendritic cells by binding Env spikes and competes neutralization by anti-HIV antibodies. *PLoS ONE* 2012; 7(11):e48781. (IF 3.73)
37. Borsetti A, Maggiorella MT, Sernicola L, **Bellino S**, Ferrantelli F, Belli R, Fulgenzi D, Mee ET, Rose NJ, Cafaro A, Ensoli B, Titti F. Influence of MHC class I and II haplotypes on the experimental infection of Mauritian cynomolgus macaques with SHIVSF162P4cy. *Tissue Antigens* 2012; 80(1):36-45. (IF 2.75)
38. Toschi E, Sgadari C, Malavasi L, Bacigalupo I, Chiozzini C, Carnei D, Compagnoni D, **Bellino S**, Falchi M, Palladino C, Leone P, Barillari G, Monini P, Ensoli B. Human immunodeficiency virus protease inhibitors reduce the growth of human tumors via a proteasome-independent block of angiogenesis and matrix metalloproteinases, *International Journal of Cancer* 2011; 128(1):82-93. (IF 5.44)
39. Luzi AM, Gallo P, Colucci A, Marcotullio S, **Bellino S**, Longo O, Ensoli B. Communication, recruitment and enrolment in the preventive and therapeutic phase I clinical trial against HIV/AIDS based on the recombinant HIV-1 Tat protein. *AIDS Care* 2011; 23(8): 939-946. (IF 1.60)
40. Sgadari C, Barillari G, Palladio C, **Bellino S**, Taddeo B, Toschi E, Ensoli B. Fibroblast Growth Factor-2 and the HIV-1 Tat Protein Synergize in Promoting

Bcl-2 Expression and Preventing Endothelial Cell Apoptosis: Implications for the Pathogenesis of AIDS-Associated Kaposi's Sarcoma. *International Journal of Vascular Medicine* 2011;452729. (IF 2.51)

41. Cafaro A, **Bellino S**, Titti F, Maggiorella MT, Sernicola L, Borsetti A, Ridolfi B, Ferrantelli F, Wiseman RW, Venzon D, Karl JA, O'Connor D, Monini P, Robert-Guroff M, Ensoli B. Impact of viral dose and major histocompatibility complex class IB haplotype on viral outcome in Tat-vaccinated mauritian cynomolgus monkeys upon challenge with SHIV89.6P. *Journal of Virology* 2010; 84(17):8953-8958. (IF 5.19)
42. Ensoli B, **Bellino S**, Tripiciano A, Longo O, Francavilla V, Marcotullio S, Cafaro A, Picconi O, Paniccia G, Scoglio A, Arancio A, Ariola C, Ruiz Alvarez MJ, Campagna M, Scaramuzzi D, Iori C, Esposito R, Mussini C, Ghinelli F, Sighinolfi L, Palamara G, Latini A, Angarano G, Ladina N, Soscia F, Mercurio VS, Lazzarin A, Tambussi G, Visintini R, Mazzotta F, Di Pietro M, Galli M, Rusconi S, Carosi G, Torti C, Di Perri G, Bonora S, Ensoli F, Garaci E. Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART. *PLoS ONE* 2010; 5(11):e13540. (IF 4.41)
43. Fanales Belasio E, Moretti S, Fiorelli V, Tripiciano A, Pavone-Cossut MR, Scoglio A, Collacchi B, Nappi F, Macchia I, **Bellino S**, Francavilla V, Caputo A, Bacillari G, Magnani M, La guardia ME, Cafaro A, Titti F, Monini P, Ensoli F, Ensoli B. HIV-1 Tat addresses Dendritic Cells to induce a predominant Th1-type Adaptive Immune Response which appears prevalent in the Asymptomatic Stage of Infection. *Journal of Immunology* 2009; 182(5):2888-2897. (IF 5.65)
44. Monini P, Sgadari C, Grosso MG, **Bellino S**, Di Biagio A, Toschi E, Bacigalupo I, Sabbatucci M, Cencioni G, Salvi E, Leone P, Ensoli B. Clinical course of classical Kaposi's sarcoma in HIV-negative patients treated with the HIV protease inhibitor Indinavir. *AIDS* 2009; 23(4):534-538. (IF 4.91)
45. Ensoli B, Fiorelli V, Ensoli F, Lazzarin A, Visintini R, Narciso P, Di Carlo A, Tripiciano A, Longo O, **Bellino S**, Francavilla V, Paniccia G, Arancio A, Scoglio A, Collacchi B, Ruiz Alvarez MJ, Tambussi G, Tassan Din C, Palamara G, Latini A, Antinori A, D'Offizi G, Giulianelli M, Giulianelli M, Carta M, Monini P, Magnani M, Garaci E. The preventive phase I trial with the HIV-1 Tat based vaccine. *Vaccine* 2009; 28(2):371-378. (IF 3.62)
46. Longo O, Tripiciano A, Fiorelli V, **Bellino S**, Scoglio A, Collacchi B, Ruiz Alvarez MJ, Francavilla V, Arancio A, Paniccia G, Lazzarin A, Tambussi G, Tassan Din C, Visintini R, Narciso P, Antinori A, D'Offizi G, Giulianelli M, Carta M, Di Carlo A, Palamara G, Giuliani M, Laguardia ME, Monini P, Magnani M, Ensoli F, Ensoli B. Phase I therapeutic trial of the HIV-1 Tat protein and long term follow-up. *Vaccine* 2009; 27(25-26):3306-3312. (IF 3.62)
47. Nappi F, Chiozzini C, Bordignon V, Borsetti A, **Bellino S**, Cippitelli M, Bacillari G, Caputo A, Tyagi M, Giacca M, Ensoli B. Immobilized HIV-1 Tat protein promotes gene transfer via transactivation independent mechanism which requires binding of Tat to viral particles. *Journal of Gene Medicine* 2009; 11(11):955-965. (IF 2.97)
48. Caputo A, Gavioli R, **Bellino S**, Longo O, Tripiciano A, Francavilla V, Sgadari C, Paniccia G, Titti F, Cafaro A, Ferrantelli F, Monini P, Ensoli F, Ensoli B. HIV-1 Tat-based vaccines: an overview and perspectives in the field of HIV/AIDS vaccine development. *International Reviews of Immunology* 2009; 28(5):285-334. (IF 2.64)
49. Borsetti A, Baroncelli S, Maggiorella MT, Moretti S, Fanales Belasio E, Sernicola L, Tripiciano A, Macchia I, Michelini Z, Belli R, Farcomeni S, Pavone-

- Cossut MR, Negri D, Caputo A, **Bellino S**, Butto' S, Titti F, Cafaro A, Ensoli B. Containment of infection in Tat vaccinated monkeys after rechallenge with a higher dose of SHIV89.6Pcy24. *Viral Immunology* 2009; 22(2):117-124. (IF 1.78)
50. **Bellino S**, Francavilla V, Longo O, Tripiciano A, Paniccia G, Arancio A, Fiorelli V, Scoglio A, Collacchi B, Campagna M, Lazzarin A, Tambussi G, Tassan Din C, Visintini R, Narciso P, Antinori A, D'Offizi G, Giulianelli M, Carta M, Di Carlo A, Palamara G, Giuliani M, Laguardia ME, Monini P, Magnani M, Ensoli F, Ensoli B. Parallel conduction of the phase I preventive and therapeutic trials based on the Tat vaccine candidate. *Reviews on Recent Clinical Trials* 2009; 4(3):195-204. (IF 1.44)
 51. [Borsetti A](#), [Baroncelli S](#), [Maggiorella MT](#), **Bellino S**, [Moretti S](#), [Sernicola L](#), [Belli R](#), [Ridolfi B](#), [Farcomeni S](#), [Negri DR](#), [Cafaro A](#), [Ensoli B](#), [Titti F](#). Viral outcome of simian-human immunodeficiency virus SHIV-89.6P adapted to cynomolgus monkeys. *Archives of Virology* 2008; 153(3):463-472. (IF 2.02)
 52. Volpi A, Gatti A, Pica F, **Bellino S**, Marsella LT, Sabato AF. Clinical and psychosocial correlates of post-herpetic neuralgia. *Journal of Medical Virology* 2008; 80(9):1646-1652. (IF 2.58)
 53. Niccoli L, **Bellino S**, Cantini F. Renal tolerability of three commonly employed non-steroidal antiinflammatory drugs in elderly patients with osteoarthritis. *Clinical and Experimental Rheumatology* 2002; 2(2):201-207. (IF 1.28)
 54. Luzzati R, Amalfitano G, Lazzarini L, Soldani F, **Bellino S**, Solbiati M, Danzi MC, Vento S, Todeschini G, Vivenza C, Concia E. Nosocomial Candidemia in Non-Neutropenic Patients at an Italian Tertiary Care Hospital. *European Journal of Clinical Microbiology & Infectious Diseases* 2000; 19(8):602-607. (IF 1.34)
 55. Dorrucchi M, Minelli G, Boros S, Manno V, Prati S, Battaglini M, Corsetetti G, Andrianou X, Riccardo F, Fabiani M, Vescio MF, Spuri M, Mateo-Urdiales A, Del Manso M, Pezzotti P, Bella A, and **the Italian Integrated Surveillance COVID-19 group**. Group A population-based cohort approach to assess excess mortality due to the spread of COVID-19 in Italy, January-May 2020. *Annali dell'Istituto Superiore di Sanità* 2022;58(1):25-33 (IF 2.21)
 56. Dorrucchi M, Minelli G, Boros S, Manno V, Prati S, Battaglini M, Corsetetti G, Andrianou X, Riccardo F, Fabiani M, Vescio MF, Spuri M, Mateo-Urdiales A, Del Manso M, Onder G, Pezzotti P, Bella A on behalf of the **Italian Integrated Surveillance COVID-19 group**. Excess mortality in Italy during the COVID-19 pandemic: assessing the differences between the first and the second wave, year 2020. *Frontiers in Public Health* 2021;31(1):37-44 (IF 2.48)
 57. Alberto Mateo-Urdiales A, Spila Alegiani S, Fabiani M, Pezzotti P, Filia A, Massari M, Riccardo F, Tallon M, Proietti V, Del Manso M, Puopolo M, Spuri M, Morciano C, D'Ancona F, Da Cas R, Battilomo S, Bella A, Menniti-Ippolito F, on behalf of the **Italian Integrated Surveillance of COVID-19 study group**, on behalf of the Italian COVID-19 vaccines registry. Risk of SARS-CoV-2 infection and subsequent hospital admission and death at different time intervals since first dose of COVID-19 vaccine administration, Italy, 27 December 2020 to mid-April 2021. *Eurosurveillance* 2021;26(25) (IF 21.29)
 58. Stuurman A, Bicler J, Carmona A, Descamps A, Díez-Domingo J, Muñoz Quiles C, Hanna Nohynek A, Rizzo C, Riera-Montes M, **DRIVE Public Partners**. Brand-specific influenza vaccine effectiveness estimates during 2019/20 season in Europe – Results from the DRIVE EU study platform. *Vaccine* 2021. (IF 4.17)
 59. Onder G, Palmieri L, Vanacore N, Giuliano M, Brusaferro S, **Italian National Institute of Health COVID-19 Mortality Group**. Nonrespiratory Complications

and Obesity in Patients Dying with COVID-19 in Italy. *Obesity* 2021;29(1):20-23. (IF 9.30)

60. Grippo F, Grande E, Maraschini A, Navarra S, Pappagallo M, Marchetti S, Cialesi R, Frova L, Orsi C, Simeoni S, Carinci A, Loreto G, Donfrancesco C, Lo Noce C, Palmieri L, Andrianou X, Mateo-Urdiales A, Onder G, Minelli G, **Italian National Institute of Health COVID-19 Mortality Group**. Evolution of pathology patterns in persons who died from COVID-19 in Italy: a national study based on death certificates. *Frontiers in medicine* 2021;8:645543. (IF 5.06)
61. Palmieri L, Palmer K, Lo Noce C, Meli P, Giuliano M, Florida M, Tamburo de Bella M, Piccioli A, Brusaferrero S, Onder G, **Italian National Institute of Health COVID-19 Mortality Group**. Differences in the clinical characteristics of COVID-19 patients who died in hospital during different phases of the pandemic: national data from Italy. *Aging Clinical and Experimental Research*. 2021;33(1):193-199. (IF 4.48)
62. Lega I, Nisticò L, Palmieri L, Caroppo E, Lo Noce C, Donfrancesco C, Vanacore N, Scattoni ML, Picardi A, Gigantesco A, Brusaferrero S, Onder G, **Italian National Institute of Health COVID-19 Mortality Group**. Psychiatric disorders among hospitalized patients deceased with COVID-19 in Italy. *Clinical medicine* 2021;35:100854. (IF 5.41)
63. Stuurman AL, Bollaerts K, Alexandridou M, Bicler J, Díez-Domingo J, Nohynek H, Rizzo C, Turunen T, Riera-Montes M, **DRIVE Public Partners**. Vaccine effectiveness against laboratory-confirmed influenza in Europe - Results from the DRIVE network during season 2018/19. *Vaccine* 2020;38(41):6455-6463. (IF 4.17)
64. Palmieri L, Vanacore N, Donfrancesco C, Lo Noce C, Canevelli M, Punzo O, Raparelli V, Pezzotti P, Riccardo R, Bella A, Fabiani M, D'Ancona FP, Vaianella L, Tiple D, Colaizzo E, Palmer K, Rezza G, Piccioli A, Brusaferrero S, Onder G, and **Italian National Institute of Health COVID-19 Mortality Group**. Clinical Characteristics of Hospitalized Individuals Dying With COVID-19 by Age Group in Italy. *The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences* 2020;75(9):1796-1800. (IF 6.05)
65. Grippo F, Navarra S, Orsi C, Manno V, Grande E, Cialesi R, Frova L, Marchetti S, Pappagallo M, Simeoni S, Di pasquale L, Carinci A, Donfrancesco C, Lo Noce C, Palmieri L, Onder G, Minelli G, **Italian National Institute of Health COVID-19 Mortality Group**. Evolution of pathology patterns in persons who died from COVID-19 in Italy: a national study based on death certificates. *Journal of clinical medicine* 2020;9(11):3459. (IF 4.24)
66. Villani ER, Carfi A, Di Paola A, Palmieri L, Donfrancesco C, Lo Noce C, Taruscio D, Meli P, Salerno P, Kodra Y, Pricci F, Tamburo de Bella M, Florida M, Onder G, **Italian National Institute of Health COVID-19 Mortality Group**. Clinical characteristics of individuals with Down syndrome deceased with CoVID-19 in Italy-A case series. *The American Journal of Medical Genetics - Part A*. 2020;182(12):2964-2970. (IF 2.80)
67. Raparelli V, Palmieri L, Canevelli M, Pricci F, Unim B, Lo Noce C, Villani ER, Rochon PA, Pilote L, Vanacore N, Onder G, **Italian National Institute of Health COVID-19 Mortality Group**. Sex differences in clinical phenotype and transitions of care among individuals dying of COVID-19 in Italy. *Biology of Sex Differences*. 2020;11(1):57. (IF 5.03)

Projects

Expert for the Assessment Report and Scientific Advice of the EMA centralized procedures for medicines marketing authorisation; Scientific coordinator of research projects; Surveillance of antibiotic resistance in Italy; Invasive Bacterial Diseases surveillance in Italy; Institutional activity supporting the outbreaks investigation; COVID-19 task force.

Memberships

Other Relevant Information